Ono Pharmaceutical Company, Ltd.
https://www.ono-pharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ono Pharmaceutical Company, Ltd.
Cash-Rich SynOx Well Placed To Compete In Hot TGCT Field
Ono’s just-announced purchase of Deciphera has put the tenosynovial giant cell tumor space under the spotlight and SynOx is making strides to stay at the head of the pack helped by significant financing.
Ono Buys Deciphera, Gaining A Commercial Cancer Drug And Infrastructure
The Japanese pharmaceutical company will acquire Deciphera for $2.4bn, gaining GIST treatment Qinlock (ripretinib).
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Ono Pharma Korea Co., Ltd., Ono Venture Investment Fund I, L.P., Ono Venture Investment, Inc., Ono Pharma UK Ltd.
- Ono Pharmaceutical Co., Ltd.
- Ono Pharma Taiwan Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice